We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.58B
AUM Growth
+$232M
Cap. Flow
+$52.5K
Cap. Flow %
0%
Top 10 Hldgs %
43.75%
Holding
149
New
7
Increased
20
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$60.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
VTRS icon
Viatris
VTRS
+$16.7M
4
MCK icon
McKesson
MCK
+$14.4M
5
TMO icon
Thermo Fisher Scientific
TMO
+$13.3M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$28.8M
2
MDCO
Medicines Co
MDCO
+$26.2M
3
INCY icon
Incyte
INCY
+$23.8M
4
ABT icon
Abbott
ABT
+$18.6M
5
CNC icon
Centene
CNC
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.08%
2 Real Estate 3.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLCM
126
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$740K 0.03%
6,000
– –
NVAX icon
127
Novavax
NVAX
$1.22B
$731K 0.03%
28,550
– –
DCOY
128
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
CYTO
129
DELISTED
Altamira Therapeutics Ltd
CYTO
$712K 0.03%
10
– –
XRN
130
Chiron Real Estate Inc
XRN
$516M
$666K 0.03%
14,680
– –
MDRX
131
DELISTED
Veradigm Inc. Common Stock
MDRX
$600K 0.02%
47,300
-126,300
-73% -$1.5M
XNCR icon
132
Xencor
XNCR
$1.59B
$478K 0.02%
20,000
– –
CLDX icon
133
Celldex Therapeutics
CLDX
$3.02B
$382K 0.01%
7,053
– –
RMR icon
134
The RMR Group
RMR
$333M
$368K 0.01%
7,441
– –
QHC
135
DELISTED
Quorum Health Corporation
QHC
$129K 0.01%
23,725
– –
LRMR icon
136
Larimar Therapeutics
LRMR
$398M
$62K ﹤0.01%
1,109
– –
ABBV icon
137
AbbVie
ABBV
$455B
$10K ﹤0.01%
156
– –
ACAD icon
138
Acadia Pharmaceuticals
ACAD
$4.55B
– –
-111,800
Closed -$3.22M
BDX icon
139
Becton Dickinson
BDX
$45.6B
– –
-64,655
Closed -$10.4M
ESPR
140
DELISTED
Esperion Therapeutics
ESPR
– –
-102,800
Closed -$1.29M
ICLR icon
141
Icon
ICLR
$12.8B
– –
-72,000
Closed -$5.41M
TXMD icon
142
TherapeuticsMD
TXMD
$23.5M
– –
-3,742
Closed -$1.08M
CMRX
143
DELISTED
Chimerix, Inc.
CMRX
– –
-308,892
Closed -$1.42M
ADMS
144
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-125,504
Closed -$2.12M
ACHN
145
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-443,851
Closed -$1.83M
MDCO
146
DELISTED
Medicines Co
MDCO
– –
-771,638
Closed -$26.2M
ELGX
147
DELISTED
Endologix Inc
ELGX
– –
-38,675
Closed -$2.21M
2 3 4 5
6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Tekla Capital Management held 149 positions worth $2.58B, up 9.9% from $2.35B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q1 2017 filing shows 7 new, 20 increased, 25 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M. The largest sale was Allergan plc, an estimated $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2017 buy was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M.
  • Tekla Capital Management added most to Amgen in Q1 2017, an estimated $60.3M increase.
  • Tekla Capital Management's biggest Q1 2017 reduction was Allergan plc, cutting an estimated $28.8M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2017, selling an estimated $26.2M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.58B portfolio in Q1 2017.
  • Tekla Capital Management opened 7 new positions and closed 10 in Q1 2017.
  • Tekla Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.58B.

Based on Tekla Capital Management's 13F filing for Q1 2017, filed 12 May 2017.